KELOWNA, British Columbia, Oct. 20, 2017 /PRNewswire/ -- Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM.CN) (FSE: 2M0)("Marapharm" or the " Company") (http://www.marapharm.com/) "Marapharm" is pleased to announce that its shares are listed on the Canadian Securities Exchange (CSE), which this week reinforced its support for firms with links to the US cannabis market in comments to a
On October 18, 2017 the Globe and Mail reported that while the Toronto Stock Exchange (TMX) threatened to kick companies with ties to US cannabis off of its exchanges, the CSE continues to welcome firms with links to the U.S. cannabis market. The TMX is not allowing cannabis companies that could violate U.S. federal law to list on the Toronto Stock Exchange or TSX Venture Exchange (TSX-V), and has initiated a review of existing issuers to determine if any should be delisted.
Issuers removed from the TSX or TSX-V may be able to find a new home on the CSE. "We obviously have a starkly different opinion when it comes to this space," said Richard Carleton, Chief Executive Officer of CNSX Markets, which runs the CSE. "This is clearly one of the biggest growth spaces in the public capital markets. We are ready and willing to work with these companies."
Speaking in response to the threats by TSX, Marapharm CEO Linda Sampson said, "The CSE is an exchange for entrepreneurs. Marapharm is proud to have selected listing on the CSE more than 2 years ago because we knew that it was the safest and strongest place to be for our shareholders. This recent disappointing move by the TMX reinforces our decision."
About Marapharm Ventures Inc.
Marapharm is a publicly traded company primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide.
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
Marijuana Industry Involvement:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.
Forward - Looking Statements:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
For Further Information:
Linda SampsonCEO +1-778-583-4476 email [email protected]
View original content:http://www.prnewswire.com/news-releases/marapharm-ventures-inc-shareholders-remain-safe-on-the-canadian-securities-exchange-300540386.html
SOURCE Marapharm Ventures Inc.
Subscribe to our Free Newsletters!
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...
Strabismus or squint is a failure of the two eyes to maintain proper alignment when looking at an ...View All